JP2023524071A5 - - Google Patents
Info
- Publication number
- JP2023524071A5 JP2023524071A5 JP2022566343A JP2022566343A JP2023524071A5 JP 2023524071 A5 JP2023524071 A5 JP 2023524071A5 JP 2022566343 A JP2022566343 A JP 2022566343A JP 2022566343 A JP2022566343 A JP 2022566343A JP 2023524071 A5 JP2023524071 A5 JP 2023524071A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- mol
- pharmaceutical composition
- lipid
- chemically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019170P | 2020-05-01 | 2020-05-01 | |
| US63/019,170 | 2020-05-01 | ||
| US202063082997P | 2020-09-24 | 2020-09-24 | |
| US63/082,997 | 2020-09-24 | ||
| PCT/US2021/030257 WO2021222801A2 (en) | 2020-05-01 | 2021-04-30 | Nucleic acids and methods of treatment for cystic fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524071A JP2023524071A (ja) | 2023-06-08 |
| JP2023524071A5 true JP2023524071A5 (https=) | 2024-05-10 |
Family
ID=78374030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566343A Pending JP2023524071A (ja) | 2020-05-01 | 2021-04-30 | 嚢胞性線維症を治療するための核酸及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12070509B2 (https=) |
| EP (1) | EP4143217A4 (https=) |
| JP (1) | JP2023524071A (https=) |
| AU (1) | AU2021263590A1 (https=) |
| CA (1) | CA3176844A1 (https=) |
| NZ (1) | NZ794954A (https=) |
| WO (1) | WO2021222801A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3458108A4 (en) | 2016-05-18 | 2020-04-22 | ModernaTX, Inc. | POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS |
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| CA3176844A1 (en) * | 2020-05-01 | 2021-11-04 | Carlos G. PEREZ-GARCIA | Nucleic acids and methods of treatment for cystic fibrosis |
| EP4208549A4 (en) | 2020-09-04 | 2025-04-16 | Verve Therapeutics, Inc. | Compositions and methods for capping RNAs |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| JP2024511463A (ja) * | 2021-03-22 | 2024-03-13 | リコード セラピューティクス，インク． | 細胞への標的送達のための組成物および方法 |
| CA3213107A1 (en) | 2021-03-23 | 2022-09-29 | Mirko HENNIG | Polynucleotide compositions, related formulations, and methods of use thereof |
| EP4334330A1 (en) | 2021-05-07 | 2024-03-13 | Helix Nanotechnologies, Inc. | Modified ribonucleic acids and uses thereof |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| US20250144237A1 (en) * | 2023-11-07 | 2025-05-08 | Cila Therapeutics Inc. | Agents, compositions and methods for enhanced delivery of nucleic acids to the cells within the respiratory system |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| US12364773B2 (en) | 2023-12-01 | 2025-07-22 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
| WO2026072721A1 (en) * | 2024-09-25 | 2026-04-02 | Carbon Biosciences, Inc. | Parvovirus compositions and methods for gene therapy |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58500845A (ja) | 1981-06-04 | 1983-05-26 | デラウェア・ケミカルス・コーポレーション | ポンプ |
| US4778810A (en) | 1987-01-08 | 1988-10-18 | Nastech Pharmaceutical Co., Inc. | Nasal delivery of caffeine |
| ES2061416T3 (es) | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| KR20040051450A (ko) * | 2002-12-12 | 2004-06-18 | 주식회사 인비보사이언스 | 알엔에이의 생체내 안정성을 증가시키는 벡터 |
| US8304529B2 (en) | 2006-07-28 | 2012-11-06 | Life Technologies Corporation | Dinucleotide MRNA cap analogs |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| CN104411338A (zh) * | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| RS57739B1 (sr) | 2013-03-14 | 2018-12-31 | Translate Bio Inc | Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| JP6506749B2 (ja) | 2013-10-22 | 2019-04-24 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| AU2014348212C1 (en) * | 2013-11-18 | 2018-11-29 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| AU2015338923B2 (en) | 2014-11-02 | 2021-10-21 | Arcturus Therapeutics, Inc. | Messenger UNA molecules and uses thereof |
| CN120842296A (zh) | 2015-09-21 | 2025-10-28 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| WO2018119163A1 (en) * | 2016-12-21 | 2018-06-28 | Payne Joseph E | Ionizable cationic lipid for rna delivery |
| EA201991747A1 (ru) * | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| US11407800B2 (en) | 2017-02-28 | 2022-08-09 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
| ES3039647T3 (en) | 2017-05-31 | 2025-10-23 | Arcturus Therapeutics Inc | Synthesis and structure of high potency rna therapeutics |
| CA3176844A1 (en) * | 2020-05-01 | 2021-11-04 | Carlos G. PEREZ-GARCIA | Nucleic acids and methods of treatment for cystic fibrosis |
| AU2022381750A1 (en) * | 2021-11-03 | 2024-05-16 | Arcturus Therapeutics, Inc. | Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosis |
-
2021
- 2021-04-30 CA CA3176844A patent/CA3176844A1/en active Pending
- 2021-04-30 NZ NZ794954A patent/NZ794954A/en unknown
- 2021-04-30 US US17/246,558 patent/US12070509B2/en active Active
- 2021-04-30 JP JP2022566343A patent/JP2023524071A/ja active Pending
- 2021-04-30 WO PCT/US2021/030257 patent/WO2021222801A2/en not_active Ceased
- 2021-04-30 EP EP21795851.1A patent/EP4143217A4/en active Pending
- 2021-04-30 AU AU2021263590A patent/AU2021263590A1/en active Pending
-
2024
- 2024-06-04 US US18/732,954 patent/US20250049950A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524071A5 (https=) | ||
| JP2024542099A5 (https=) | ||
| Persson et al. | Patient‐controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. | |
| EP1785145A1 (en) | Transnasal composition having immediate action and high absorbability | |
| CN114404391B (zh) | 一种纳米粒及其制备方法和用途 | |
| Oku et al. | Evaluation of drug targeting strategies and liposomal trafficking. | |
| WO2020028475A1 (en) | Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof | |
| PT92995B (pt) | Metodo para o tratamento da disfuncao leucocita com gm-csf | |
| EP1642591A1 (en) | MEDICINAL COMPOSITION CONTAINING NF-kAPPA B DECOY FOR TREATING AND PREVENTING RESPIRATORY DISEASES AND METHOD OF USING THE SAME | |
| KR20220149400A (ko) | 이황화 결합을 갖는 양이온성 지질을 사용하여 약물을 전달하기 위한 나노입자 조성물 및 그 제조방법 | |
| CN114652683A (zh) | 一种Mdivi-1纳米长循环脂质体及其制备方法和应用 | |
| JP2008512444A (ja) | 神経変性状態の治療のための、両親媒性弱塩基様テンパミンを含むリポソーム製剤 | |
| JP7354132B2 (ja) | マイクロ粒子／ナノ粒子が粘液層を通って移動するのを強化するためのアルギネートオリゴマーの使用 | |
| CN117442552A (zh) | 一种淋巴结内t细胞区靶向纳米粒及其水凝胶 | |
| TW202021574A (zh) | 含有抗精神病藥物的緩釋藥物組合物及其用途 | |
| WO2023169506A1 (zh) | 编码新型冠状病毒S蛋白的mRNA疫苗 | |
| WO2019024841A1 (zh) | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药物组合物 | |
| Remington et al. | Combined budesonide/formoterol turbuhaler treatment of asthma | |
| CN102138900B (zh) | 奥沙碘铵脂质体固体制剂 | |
| Saeinasab et al. | Encapsulation in respiratory system | |
| CN118512414A (zh) | 一种具有器官靶向能力的低免疫原性脂质纳米粒及其制备方法与应用 | |
| CN121846285A (zh) | Slc39a1特异性调控剂在制备治疗急性呼吸窘迫综合征药物中的应用 | |
| CN116370438A (zh) | 一种载药复合纳米粒子MSN-Ber的制备方法以及在制备治疗肺纤维化的药物中的应用 | |
| CN121570421A (zh) | 一种具有协同抗肿瘤功效的温敏脂质体及其制备方法和应用 | |
| Watanabe et al. | A case of severe digitalis poisoning due to accidental intake of a massive dose of methyldigoxin |